Tibet Nodikang: intends to invest 60 million US dollars in Accuredit Therapeutics.

Tibet Nuo Di Kang Pharmaceutical plans to invest 60 million US dollars through its wholly-owned subsidiary TopRidge Pharma Limited in Accuredit Therapeutics Limited, holding a 40.82% stake; the controlling shareholder's affiliated company Kangzhe Pharmaceutical will invest 15 million US dollars through its subsidiary, holding a 10.20% stake, forming a related party transaction. The target company's core business is in Rui Zheng Genetics, focusing on non-viral vector in vivo gene editing drugs. ART001 has been approved for IND in China and the United States and is conducting clinical trials; ART002 is conducting IIT clinical research. After the completion of the transaction, the company's consolidated financial statements will change. As the target company's products are still in the research and development stage, it will affect the profitability in the short term. The proposal has been reviewed and disclosed.